Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma Meeting Abstract
| Authors: | Rosenberg, J. E.; Powles, T.; Sonpavde, G. P.; Loriot, Y.; Duran, I.; Lee, J. L.; Matsubara, N.; Vulsteke, C.; Castellano, D. E.; Mamtani, R.; Wu, C.; Matsangou, M.; Campbell, M. S.; Petrylak, D. P. |
| Abstract Title: | Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680301337 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.4516 |
| Notes: | Meeting Abstract: 4516 -- Meeting also held virtually -- Source: Wos |
